Vonoprazan-Based Triple Tx Feasible for H. pylori

This article originally appeared here.
Share this content:
Vonoprazan-Based Triple Tx Feasible for <i>H. pylori</i>
Vonoprazan-Based Triple Tx Feasible for H. pylori

THURSDAY, Aug. 25, 2016 (HealthDay News) -- The potassium-competitive acid blocker vonoprazan-based triple therapy seems safe and effective compared with conventional proton pump inhibitor (PPI)-based triple therapy as first-line treatment against Helicobacter pylori, according to a study published online Aug. 17 in the Journal of Digestive Diseases.

Satoki Shichijo, M.D., Ph.D., from the University of Tokyo, and colleagues performed a multicenter study involving 2,715 patients who received first-line H. pylori eradication therapy. Vonoprazan-based triple therapy was compared with conventional PPI-based triple therapy.

The researchers found that eradication rates were 87.2 and 72.4 percent for vonoprazan-based and conventional PPI-based therapy, respectively (P < 0.01). There were 10 cases of diarrhea, six of nausea/vomiting, and five of rash in the vonoprazan-based therapy group; these rates were not higher than those in the conventional PPI-based group.

"Vonoprazan-based triple therapy is feasible; it showed a higher eradication rate than conventional PPIs as a first-line regimen," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Single-Payer Health System Bill Moves Forward in California

Single-Payer Health System Bill Moves Forward in California

Not yet clear where money for the single-payer system would come from

Regorafenib Approved for Hepatocellular Carcinoma

Regorafenib Approved for Hepatocellular Carcinoma

It is the first approved treatment for HCC in almost a decade

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Rates of worsening low in patients receiving aflibercept, bevacizumab, or ranibizumab

is free, fast, and customized just for you!

Already a member?

Sign In Now »